{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=20", "query": { "intervention": "Open Label Extension Study", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 2082, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T14:19:20.341Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04966741", "title": "Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bardet-Biedl Syndrome", "POMC Deficiency Obesity", "PCSK1 Deficiency Obesity", "LEPR Deficiency Obesity" ], "interventions": [ { "name": "Setmelanotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "2 Years to 5 Years" }, "enrollment_count": 12, "start_date": "2022-03-08", "completion_date": "2024-11-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 3, "location_summary": "Aurora, Colorado • New York, New York • Marshfield, Wisconsin", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Marshfield", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04966741" }, { "nct_id": "NCT00948766", "title": "Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Rivastigmine 4.6 mg/24 h (5 cm^2)", "type": "DRUG" }, { "name": "Rivastigmine 9.5 mg/24 h (10 cm^2)", "type": "DRUG" }, { "name": "Rivastigmine 13.3 mg/24 h (15 cm^2)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 716, "start_date": "2009-07", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 93, "location_summary": "Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00948766" }, { "nct_id": "NCT06941844", "title": "A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "DT120", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Definium Therapeutics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 149, "start_date": "2025-04-14", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 22, "location_summary": "Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06941844" }, { "nct_id": "NCT05254457", "title": "Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plantar Fibromatosis" ], "interventions": [ { "name": "EN3835", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2022-02-14", "completion_date": "2024-03-21", "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 27, "location_summary": "Bakersfield, California • Fresno, California • La Mesa, California + 22 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05254457" }, { "nct_id": "NCT07227311", "title": "A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2026-04-15", "completion_date": "2030-08-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 12, "location_summary": "Los Alamitos, California • Torrance, California • Whittier, California + 9 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227311" }, { "nct_id": "NCT02432144", "title": "A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sly Syndrome", "MPS VII", "Mucopolysaccharidosis", "Mucopolysaccharidosis VII" ], "interventions": [ { "name": "UX003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ultragenyx Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 12, "start_date": "2015-11-10", "completion_date": "2019-01-14", "has_results": true, "last_update_posted_date": "2020-07-30", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 4, "location_summary": "Oakland, California • Orange, California • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02432144" }, { "nct_id": "NCT02277444", "title": "A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Juvenile" ], "interventions": [ { "name": "Golimumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 130, "start_date": "2014-12-22", "completion_date": "2024-09-27", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 14, "location_summary": "San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277444" }, { "nct_id": "NCT04657198", "title": "Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSVPreF3 OA investigational vaccine (GSK3844766A)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 126, "start_date": "2020-12-09", "completion_date": "2021-10-25", "has_results": true, "last_update_posted_date": "2022-06-29", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 7, "location_summary": "Lenexa, Kansas • Elkridge, Maryland • Omaha, Nebraska + 4 more", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Elkridge", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Rochester", "state": "New York" }, { "city": "Hickory", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657198" }, { "nct_id": "NCT03131219", "title": "Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atypical Hemolytic Uremic Syndrome (aHUS)" ], "interventions": [ { "name": "Ravulizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 34, "start_date": "2017-08-31", "completion_date": "2022-12-20", "has_results": true, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 6, "location_summary": "Hollywood, Florida • Atlanta, Georgia • Detroit, Michigan + 3 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03131219" }, { "nct_id": "NCT04188509", "title": "Open-Label Extension of Voxelotor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 162, "start_date": "2019-11-18", "completion_date": "2024-11-01", "has_results": true, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-29T14:19:20.341Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04188509" } ] }